for and Chuck, of morning, Thank and of the following steps I the this everyone. the good Pfizer will separation expected continued growth taking Upjohn for our accelerated morning from Pfizer advancement later to our the position pipeline you, This year, we're performance speak about year.
business, details the quarter revenue quarter solid highlighted full and results. will Pfizer, generated transformational we regarding productive Frank results which These our year a our provide X% performance exceptional the XXXX year guidance. the was for fourth then new for in following become will XXXX were year separation by our and for financial growth of Upjohn. the and operational X% Biopharma Pfizer which expected fourth the financial
came strong increases, performance in others. point operational Eliquis, our volume XX% Biopharmaceutical our Xtandi, I Biopharma emerging primarily all outstanding the growth XXXX from that again, in Biopharma's markets generated group, pricing. continued growth driven growth also Once among growth out includes would drivers. from was key Vyndaqel not Xeljanz, Ibrance, XXXX. This by
X% impact results. had pricing in Biopharma's fact In the negative
very strong year revenues increased its For full become reached growth position not a also class use still significant US a in Ibrance with US has operationally XX% of nearly in US. seen see In a where sale. levels XXXX outside and syndicate performance the Ibrance retained billion strong, nearly opportunities robust leadership yet and the in the $X global realized the was inhibitors product. XX% the CDK to the countries we of year Ibrance
number X/X XX globally Overall Ibrance countries and the has approved inhibitor more prescribed than XXX,XXX CDK in reached than is one more is patients.
For alliance royalty for our income were the revenues full and in in totaled billion Xtandi when sales nearly US ex-US the with up $X.X on XXXX. year, combined XX%
novel year The class uptake recognition market data hormone Xtandi but well prostate confidence in growth an indication over gross growing as non-metastatic of Xtandi's XX% therapy increasingly castration is due vast with year to was the cancer prescriptions. resistant in CRTC. as total prescriber in leading competitive the continued brand in strong share of
Xtandi anticoagulant and in three distinct of primarily in US. There to so the prostate to indication market Pfizer adoption fibrillation, metastatic is Eliquis continue far share oral well as billion. is operationally only an alarm cancer approved castration XX% was types up continued treatment the prostate This now by revenues the the oral well. first increase atrial sensitive Xtandi FDA global driven in growth was non-valvular perform as gains. serving by $X.X cancer.
revenues the oral with across operationally in performance Eliquis markets leader increasing had billion. a now globe. Xeljanz $X.X strong anticoagulant is XX to global the XX%
arthritis markets. to positive new in across and ulcerative launch we and uptake rheumatoid are arthritis ulcerative continued all very psoriatic the indications, continue colitis. with pleased psoriatic We And arthritis, colitis
revenue $XX approval the contributed Vyndaqel for May for to in XXXX Looking its up and the of at Overall, XXXX. cardiomyopathy. ramp medicine first in our in US million disease of business, ATTR the following treatment having continues launch this nicely kind
prior helped efforts drive X% to fourth by quarter, the X% to end awareness of compared the with the disease Our rate launch. diagnosis
patients X,XXX received have do As have of than drug. than include the the patients the more not more for These been XXXX than access early program. in hundred and X,XXX X,XXX received approximately have Vyndaqel patients diagnosed, who still end are the numbers prescription of more patients
revenues immune-competent concern pharmacist. Prevnar $X.X the billion. published older with its XX to decision a CDC were assistant, making cert PCV XX to X% highlighting US up age physician's updated decision vaccinate recommendation that report, adults The physician, nurse mortality XX and also practitioner clinical or to a operationally Global morbidity November with and in for patient weekly the
our beginning at have is focus Looking recovery the shape taking US. line portfolio, a in to on manufacturing impact the top our injectibles and positive sterile on
and from our remediation fourth for progress throughout the declined while increased We injectables X% portfolio improvement XXXX. continued with it the Of quarter. have year, note, made during full sterile modernization and X% expect revenue solid operationally global operationally
Additionally, anticipate XX% portfolio percentage in more of is than in stock And this today. our to injectibles continue will XXXX. we increase
the XX% to of portfolio This XX% Our a in grew full $XXX million was and US, operationally Retacrit of the to gradual global thanks by biosimilars launch growth for driven largely uptake Inflectra. the year.
growth was decline the by partially The offset international by driven markets in Inflectra. mainly US in
from an be at announced a biosimilars. products. launches substantially of [indiscernible] the All the week, originator oncology compared launch XXXX the in Last to discounted expect available price launch Trazimera. with three next the three products biosimilars market, we additional with we expect contribution We month US of in will antibody and monoclonal
constitute our year share non-reimbursed China. were China primarily partially significant Lyrica The is channels, on well in which Viagra as China. The offset for by driven billion. operationally X% operational the was in Lipitor XX% and Celebrex, in by growth advent growth market which in Upjohn as generic down in the $XX.X revenue was year competition to during US, Full headwind of key business the
planning we remains Viatris Pfizer completion making Mylan, proposed transaction. upon current on a and combination are track December, mid-XXXX. former progress Read James for join good We for Board Ian will In the of Chairman with Pfizer that which Kilts Upjohn's Director the pre-integration with of Directors announced
on CFO Mylan counterparts with We selection of process. our the are also working closely
director of the quarter. this We CFO of end the by expect appointments to announce both the third and the
We which have Viatris, combine commercial pipeline. with capabilities will and confidence brands Upjohn's strong iconic in Mylan's terrific great
are progress with very we Turning R&D, with pleased pipeline. making now to we our the remain
expecting key are hoping make our five key setting to patients of which potential study to this up proof areas up new XXXX, starts concept for We readouts, therapeutic readouts. in several data an have from to of treatment We contributions pivotal anticipate as all XX results for exciting options. as XX pivotal the well study year from and with clinical
those of some highlight now will events. expected I
regulatory expect breast double programs to number to successful, could these If programs, eligible continue Ibrance and early the driven patients our powers in XXXX approval, of following from B, Ibrance. late respectively. and event cancer We benefit out Penelope to XXXX read two early and
Braftovi arm XXXX. and study Phase CRC patients the The and X submitted safety combination be from efficacy the untreated half evaluating ongoing. in open for ANCHOR the previously label Results Medical with BRAFvXXXE the in currently metastatic the cetuximab presentation Congress of Mektovi study, at colorectal will mutant is single and of cancer of second
moderate year. conclusion with abrocitinib, inhibitor the to in severe Phase findings investigational look of projected for of submission the successful is the the subsequent Pending treatment For third JADE XXXX we core regulatory Phase the months. the trial forward atopic to quarter X JAK-X U.S. in studies sharing our following coming compared X dermatitis, for line of markets from the top in later
on topical dupilumab The in placebo the with atopic a of abrocitinib the with dermatitis in severe dupilumab designed adults is but moderate medicated moderate assess or and atopic has also it to assess severity safety efficacy therapy endpoint, severe adults background each is key to abrocitinib to study secondary study on therapy. of This background designed on to effect compared with dermatitis. topical
to expected from up proof in are There leading concept of pipeline. five readouts immune-kinase our XXXX industry
into oral trials. and tech include with is for as potential oral POC JAK-X for for hope and psoriatic well psoriasis atopic TYKX Our topical dermatitis, Phase advance readouts of in to several psoriasis. JAK-X arthritis for for TYKX formulation Vitiligo, as This and X this
This great make the has formulation to the as we to potential strategy example unique our disease, disease. that where difference, as to think we a and forms potential most is the milder purposefully the has it believe to molecule treat a match of of well
therapy start expected Phase that with gene Our data Haemophilia the is A year. support X X/X is advancing promising platform this Phase to
second our Haemophilia Phase study. ongoing following the X pivotal be B therapy would This study gene
data last June. conference DMD is program additional therapy gene our Dystrophy progress gathering the patient on research Muscular addition, building robust In current project the at
We study for pivotal in half an first are start in preparing this year. X POC of of expected the XXXX Phase the half second and
advancement XX-valent a biologics this license a We studies our year. pneumococcal potential application conjugate submit end to the Phase look compared by Pfizer's the for on the to and in investigational track the potential XX-valent. vaccine significant candidate remain FDA adults of with represents successfully forward to candidate completing X
five disease the infants disease may approved XX% against cause pneumococcal XX% adults in strains more in If coverage in X the and successful Phase that strains more serotypes provide and the States. causing United additional invasive in approximately
For Virus second maternal X. Phase Respiratory an vaccine followed in are of our preparing for the for progression quarter to we POC potentially RSV, by expected swift Syncytial XXXX,
forward in more investor we summary, to strong momentum day XX. and that XXXX. We look upcoming our In on look momentum, continuing sharing to our with pipeline forward updates on March we during XXXX finished
change legacy During breakthroughs an on the will bold we took our patients' R&D innovation to into generated that strong financial year powerhouse reshape our advanced a performance, Pfizer further and lives. delivering solid actions pipeline that build of
to provide the the will details I for it outlook of Now, Frank quarter on Frank? remainder over to our XXXX. turn and
